Baseline characteristics and comparison of treatment intention
| Characteristic . | Whole cohort (N = 125) . | Treatment intention . | ||
|---|---|---|---|---|
| Chemotherapy-alone (n = 62) . | CMT (n = 63) . | P . | ||
| Age, median (range), y | 34 (18-78) | 37 (18-70) | 33 (19-70) | .39 |
| Male sex | 73 (58.4%) | 35 (56.5%) | 38 (60.3%) | .66 |
| Histology | ||||
| Nodular sclerosis | 85 (68.0%) | 40 (64.5%) | 45 (71.4%) | .38 |
| Mixed cellularity | 5 (4.0%) | 2 (3.2%) | 3 (4.8%) | |
| Lymphocyte-rich | 4 (3.2%) | 1 (1.6%) | 3 (4.8%) | |
| Classical | 31 (24.8%) | 19 (30.6%) | 12 (19.0%) | |
| Stage | ||||
| IA | 7 (5.6%) | 2 (3.2%) | 5 (7.9%) | .01 |
| IB | 1 (0.8%) | 0 | 1 (1.6%) | |
| IIA | 77 (61.6%) | 32 (51.6%) | 45 (71.4%) | |
| IIB | 40 (32.0%) | 28 (45.2%) | 12 (19.0%) | |
| Prognosis | ||||
| Favorable | 36 (30.8%) | 16 (27.6%) | 20 (33.9%) | .46 |
| Unfavorable | 81 (69.2%) | 42 (72.4%) | 39 (66.1%) | |
| Disease bulk | ||||
| Bulky | 43 (34.4%) | 20 (32.3%) | 23 (36.5%) | .62 |
| Non-bulky | 82 (65.6%) | 42 (67.7%) | 40 (63.5%) | |
| Treatment intention | ||||
| CMT | 63 (50.4%) | |||
| Chemotherapy-alone | 62 (49.6%) | |||
| Treatment cycles | ||||
| ≤4 cycles | 59 (47.2%) | 9 (14.5%) | 50 (79.4%) | <.001 |
| 6 cycles | 52 (41.6%) | 41 (66.1%) | 11 (17.5%) | |
| Novel therapy | 14 (11.2%) | 12 (19.4%) | 2 (3.2%) | |
| Treatment received | ||||
| CMT | 61 (48.8%) | 2 (3.2%) | 59 (93.7%) | <.001 |
| Chemotherapy-alone | 64 (51.2%) | 60 (96.8%) | 4 (6.3%) | |
| PET2 response | ||||
| Negative (DS 1-2) | 86 (78.2%) | 38 (70.4%) | 48 (85.7%) | .051 |
| Positive (DS ≥3) | 24 (21.8%) | 16 (29.6%) | 8 (14.3%) | |
| Negative (DS 1-3) | 95 (86.4%) | 43 (79.6%) | 52 (92.9%) | .04 |
| Positive (DS ≥4) | 15 (13.6%) | 11 (20.4%) | 4 (7.1%) | |
| Treatment complications | ||||
| Dose delay | 26 (20.8%) | 14 (22.6%) | 12 (19.0%) | .63 |
| BPT | 32 (25.6%) | 14 (22.6%) | 18 (28.6%) | .44 |
| Hospitalization | 27 (21.6%) | 14 (22.6%) | 13 (20.6%) | .79 |
| BPT hospitalization | 9 (7.2%) | 3 (4.8%) | 6 (9.5%) | .31 |
| Relapsed/refractory | 17 (13.6%) | |||
| Salvage treatment | ||||
| auto-SCT | 12 (9.6%) | |||
| allo-SCT | 1 (0.8%) | |||
| Death | ||||
| Total | 5 (4%) | |||
| HL related death | 3 (3%) | |||
| Characteristic . | Whole cohort (N = 125) . | Treatment intention . | ||
|---|---|---|---|---|
| Chemotherapy-alone (n = 62) . | CMT (n = 63) . | P . | ||
| Age, median (range), y | 34 (18-78) | 37 (18-70) | 33 (19-70) | .39 |
| Male sex | 73 (58.4%) | 35 (56.5%) | 38 (60.3%) | .66 |
| Histology | ||||
| Nodular sclerosis | 85 (68.0%) | 40 (64.5%) | 45 (71.4%) | .38 |
| Mixed cellularity | 5 (4.0%) | 2 (3.2%) | 3 (4.8%) | |
| Lymphocyte-rich | 4 (3.2%) | 1 (1.6%) | 3 (4.8%) | |
| Classical | 31 (24.8%) | 19 (30.6%) | 12 (19.0%) | |
| Stage | ||||
| IA | 7 (5.6%) | 2 (3.2%) | 5 (7.9%) | .01 |
| IB | 1 (0.8%) | 0 | 1 (1.6%) | |
| IIA | 77 (61.6%) | 32 (51.6%) | 45 (71.4%) | |
| IIB | 40 (32.0%) | 28 (45.2%) | 12 (19.0%) | |
| Prognosis | ||||
| Favorable | 36 (30.8%) | 16 (27.6%) | 20 (33.9%) | .46 |
| Unfavorable | 81 (69.2%) | 42 (72.4%) | 39 (66.1%) | |
| Disease bulk | ||||
| Bulky | 43 (34.4%) | 20 (32.3%) | 23 (36.5%) | .62 |
| Non-bulky | 82 (65.6%) | 42 (67.7%) | 40 (63.5%) | |
| Treatment intention | ||||
| CMT | 63 (50.4%) | |||
| Chemotherapy-alone | 62 (49.6%) | |||
| Treatment cycles | ||||
| ≤4 cycles | 59 (47.2%) | 9 (14.5%) | 50 (79.4%) | <.001 |
| 6 cycles | 52 (41.6%) | 41 (66.1%) | 11 (17.5%) | |
| Novel therapy | 14 (11.2%) | 12 (19.4%) | 2 (3.2%) | |
| Treatment received | ||||
| CMT | 61 (48.8%) | 2 (3.2%) | 59 (93.7%) | <.001 |
| Chemotherapy-alone | 64 (51.2%) | 60 (96.8%) | 4 (6.3%) | |
| PET2 response | ||||
| Negative (DS 1-2) | 86 (78.2%) | 38 (70.4%) | 48 (85.7%) | .051 |
| Positive (DS ≥3) | 24 (21.8%) | 16 (29.6%) | 8 (14.3%) | |
| Negative (DS 1-3) | 95 (86.4%) | 43 (79.6%) | 52 (92.9%) | .04 |
| Positive (DS ≥4) | 15 (13.6%) | 11 (20.4%) | 4 (7.1%) | |
| Treatment complications | ||||
| Dose delay | 26 (20.8%) | 14 (22.6%) | 12 (19.0%) | .63 |
| BPT | 32 (25.6%) | 14 (22.6%) | 18 (28.6%) | .44 |
| Hospitalization | 27 (21.6%) | 14 (22.6%) | 13 (20.6%) | .79 |
| BPT hospitalization | 9 (7.2%) | 3 (4.8%) | 6 (9.5%) | .31 |
| Relapsed/refractory | 17 (13.6%) | |||
| Salvage treatment | ||||
| auto-SCT | 12 (9.6%) | |||
| allo-SCT | 1 (0.8%) | |||
| Death | ||||
| Total | 5 (4%) | |||
| HL related death | 3 (3%) | |||
allo-SCT, allogeneic stem cell transplant; auto-SCT, autologous stem cell transplant.